GCS‑NeuroCOVID paediatric substudy
Research type
Research Study
Full title
Global Consortium Study of Neurological Dysfunction in COVID‑19 - paediatric substudy
IRAS ID
287455
Contact name
Hari Krishnan
Contact email
Sponsor organisation
Birmingham Women's and Children's NHS Foundation Trust
Duration of Study in the UK
1 years, 11 months, 31 days
Research summary
As the COVID-19 pandemic evolves worldwide, reports of a spectrum of mild to severe neurological syndromes among patients infected with SARS-CoV-2 are emerging. The Neurological Manifestations of COVID-19 pediatrics study is a multinational, observational study with three planned tiers. The tier 1 study (for which this application is for) is based on using routinely collected observational data collection from children <18 years of age who are admitted to a hospital with confirmed or suspected COVID-19. There are two aims for Tier 1: (1) quantify neurological symptoms and diagnoses during hospitalization; (2) examine associations between COVID-19-directed therapies and patient characteristics with outcomes.
The intention is for NHS organisations within England and Wales to share de-identified data to the lead centre in Birmingham, UK, who will in turn liaise with and be conduit for information flow of lead centre for analysis in the USA (Pittsburgh). Local units will retain identifiers which will not be sent either to Birmingham or to the USA.
REC name
South Central - Berkshire B Research Ethics Committee
REC reference
20/SC/0408
Date of REC Opinion
16 Nov 2020
REC opinion
Favourable Opinion